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Association ofTGF-f)1 expression with the effects oftamoxifen on estrogen
receptor positive and negative breast cancer cells
Sir - We thank Dr Benson and Dr Baum for their comments
regarding our paper (Perry et al., l995a). We are familiar
with their studies on the potential role of transforming
growth factor (TGF)-f3, produced by stromal fibroblasts in
tamoxifen-induced growth inhibition. As our work, and the
work of others (Knabbe et al., 1987), indicates that tamoxifen
has direct effects on epithelial cells, we agree that tamoxifen
may act via both functional autocrine and paracrine
inhibitory loops involving TGF-fl. The relative importance
of autocrine and or paracnine TGF-fl, secretion in tamoxifen-
induced growth inhibition may be dependent on the cell line
and the dose and duration of tamoxifen treatment.
Knabbe et al. (1987) have shown that oestrogen receptor
(ER)-positive MCF-7 cells respond to anti-oestrogen (100 nm
4-hydroxytamoxifen), but ER-negative MDA-231 cells do
not. However, other studies have shown that ER-negative
cells, including MDA-231, respond to tamoxifen concentra-
tions of I pum or greater (Taylor et al., 1984). We have also
noted that. although MCF-7 cells are more sensitive to
tamoxifen than MDA-231 cells, MDA-231 cells do respond
to micromolar concentrations of tamoxifen (Perry et al..
1995b). The response of ER-negative cells to tamoxifen is not
surprising as several clinical studies have shown that the
effectiveness of tamoxifen is independent of ER status (for
review see Jaiyesimi et al.. 1995). As we were interested in
studying the potential role of TGF-f, in ER-negative as well
as ER-positive cells. we chose a concentration of tamoxifen
(10 pm) that possessed significant activity against both cell
lines. Although this tamoxifen concentration is relatively high
compared with the serum levels achieved in patients on
standard dose (20-80 mg day-1) therapy, anti-oestrogens
accumulate in human tissues and tumours at levels 10-60
times higher than in serum (Lien et al.. 1991). Thus.
intratumoral tamoxifen concentrations may be in the
micromolar range. We agree that a 10 um tamoxifen
concentration is likely in a range in which the effects are
no longer solely dependent on ER. Indeed. this is supported
by our results. whereby 10 pm tamoxifen had similar effects
on TGF-fi, expression in both the ER-positive MCF-7 and
ER-negative MDA-231 cell lines. Also, the addition of
oestrogen failed to inhibit tamoxifen-induced TGF-fl1
expression in either cell line, again indicating that tamoxifen
at this concentration appears to induce TGF-fl1 through an
ER-independent mechanism. We concur with the conclusions
of Taylor et al. (1984) and Sutherland et al. (1986), that
tamoxifen appears to have both ER- and non-ER-dependent
activity.
Many, if not all. cytotoxic agents are capable of inducing
programmed cell death (apoptosis). This includes agents with
different mechanisms of action and that cause damage to
different targets. However, we do not agree with Dr Benson
and Dr Baum that the apoptotic activity of tamoxifen at a
10 !LM concentration was strictly due to non-specific damage
unrelated to enhancement of TGF-f3, production. As our
work demonstrates, the amount of TGF-f31 induced by
tamoxifen highly correlated with the amount of DNA
cleavage. In addition, tamoxifen induced DNA cleavage
was abrogated by the addition of an anti-TGF-f, antibody.
This demonstrates that TGF-fl, does have an important role
in tamoxifen-induced apoptosis in both ER-positive and ER-
negative cells.
We agree that current evidence suggests that tamoxifen
may act via a post-transcriptional mechanism at lower
concentrations and a transcriptional mechanism at higher
concentrations.
Whether such mechanistic differences are important in
determining the therapeutic effectiveness in vivo remain to be
determined.
Roger R Perry,
Yuan Kang,
Bridget Greaves,
Division of Surgical Oncology,
Eastern Virginia Medical School,
Norfolk, Virginia 23507, USA
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